SETTING: The impact of the human immunodeficiency virus (HIV) on multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in sub-Saharan Africa, where extensive rollout of highly active antiretroviral therapy (HAART) has occurred, remains unclear. OBJECTIVE: To compare the time to initial culture conversion among patients with and those without HIV infection in a setting of individualized MDR-TB care in Botswana. DESIGN: Prospective cohort study of MDR-TB patients receiving ambulatory, integrated TB-HIV care at two public clinics in Botswana. The time to culture conversion was compared by HIV status using Cox proportional hazard ratios (HRs). RESULTS: A total of 40 HIV-infected and 30 non-HIV-infected patients with MDR-TB and follow-up cultures were identified. The median time to initial culture conversion was 78 days (interquartile range [IQR] 42-186) for HIV-infected and 95 days (IQR 70-133) for non-HIV-infected individuals (log rank P > 0.5; unadjusted HR 0.9, 95%CI 0.5-1.5). Adjusting for age, sex, treatment history and number of active anti-tuberculosis drugs did not change this result (adjusted HR 0.8, 95%CI 0.4-1.4). CONCLUSION: We found no difference in the proportion of or time to initial sputum culture conversion between an HIV-infected and a non-infected cohort of MDR-TB patients in Botswana, suggesting that outcomes may be comparable in similar settings with access to individualized anti-tuberculosis treatment and HAART.
SETTING: The impact of the human immunodeficiency virus (HIV) on multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in sub-Saharan Africa, where extensive rollout of highly active antiretroviral therapy (HAART) has occurred, remains unclear. OBJECTIVE: To compare the time to initial culture conversion among patients with and those without HIV infection in a setting of individualized MDR-TB care in Botswana. DESIGN: Prospective cohort study of MDR-TB patients receiving ambulatory, integrated TB-HIV care at two public clinics in Botswana. The time to culture conversion was compared by HIV status using Cox proportional hazard ratios (HRs). RESULTS: A total of 40 HIV-infected and 30 non-HIV-infectedpatients with MDR-TB and follow-up cultures were identified. The median time to initial culture conversion was 78 days (interquartile range [IQR] 42-186) for HIV-infected and 95 days (IQR 70-133) for non-HIV-infected individuals (log rank P > 0.5; unadjusted HR 0.9, 95%CI 0.5-1.5). Adjusting for age, sex, treatment history and number of active anti-tuberculosis drugs did not change this result (adjusted HR 0.8, 95%CI 0.4-1.4). CONCLUSION: We found no difference in the proportion of or time to initial sputum culture conversion between an HIV-infected and a non-infected cohort of MDR-TB patients in Botswana, suggesting that outcomes may be comparable in similar settings with access to individualized anti-tuberculosis treatment and HAART.
Authors: Joia S Mukherjee; Michael L Rich; Adrienne R Socci; J Keith Joseph; Felix Alcántara Virú; Sonya S Shin; Jennifer J Furin; Mercedes C Becerra; Donna J Barry; Jim Yong Kim; Jaime Bayona; Paul Farmer; Mary C Smith Fawzi; Kwonjune J Seung Journal: Lancet Date: 2004-02-07 Impact factor: 79.321
Authors: E E Telzak; K D Chirgwin; E T Nelson; J P Matts; K A Sepkowitz; C A Benson; D C Perlman; W M El-Sadr Journal: Int J Tuberc Lung Dis Date: 1999-04 Impact factor: 2.373
Authors: M A Fischl; G L Daikos; R B Uttamchandani; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S A Oldham Journal: Ann Intern Med Date: 1992-08-01 Impact factor: 25.391
Authors: T R Frieden; L F Sherman; K L Maw; P I Fujiwara; J T Crawford; B Nivin; V Sharp; D Hewlett; K Brudney; D Alland; B N Kreisworth Journal: JAMA Date: 1996-10-16 Impact factor: 56.272
Authors: Nicola M Zetola; Nenad Macesic; Sanghyuk S Shin; Sanghyuk Shin; Alexandra Peloso; Ronald Ncube; Jeffrey D Klausner; Chawangwa Modongo; Ronald G Collman Journal: BMC Infect Dis Date: 2014-07-22 Impact factor: 3.090
Authors: Hyun Oh Park; Sung Hwan Kim; Seong Ho Moon; Joung Hun Byun; Jong Woo Kim; Chung Eun Lee; Jong Duk Kim; In Seok Jang; Jun Ho Yang Journal: Infect Chemother Date: 2016-11-21
Authors: Moses M Ngari; Susanne Schmitz; Christopher Maronga; Lazarus K Mramba; Michel Vaillant Journal: BMC Med Res Methodol Date: 2021-04-27 Impact factor: 4.615
Authors: Olanrewaju Oladimeji; Petros Isaakidis; Olusegun J Obasanya; Osman Eltayeb; Mohammed Khogali; Rafael Van den Bergh; Ajay M V Kumar; Sven Gudmund Hinderaker; Saddiq T Abdurrahman; Lovett Lawson; Luis E Cuevas Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240